IMS Health

Iqvia Holdings Inc (NYSE: Q), formerly known as Quintiles, merged with IMS Health last year to combine its data assets and tools to better compete in the post-Cures Act environment. The Analyst KeyBanc Capital Markets' Donald Hooker downgraded Iqvia's stock rating from Overweight to...

The 2016 election season has brought the topic of prescription drug pricing and profits into the limelight. Most patients paying for medication are acutely aware of the billions of dollars of global drug sales that the top pharmaceutical companies rake in each year. With the elections now less than...

Argus maintains its Buy rating on Quintiles Transnational Holdings Inc (NYSE: Q) shares. The brokerage also lifted its price target from $75 to $85. The move comes after the company delivered better-than-estimated second-quarter results and an increased outlook on July 27. Analysts Jacob Kilstein...

U.S. stocks ended the week on a sour note as investors continue to sell many momentum names. Not helping the bull case was the much anticipated Jobs report number which failed to "wow" the market, coming in relatively in-line with expectations. The Dow suffered a triple digit point loss and...

The leading drug makers aren’t doing enough to gain market share in emerging markets, according to a report that was issued by IMS Health, a research company based in Norwalk, Conn., that tracks prescriptions and other data on drug sales. That’s according to an article in today’s New York Times....